S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.63 (+0.79%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.63 (+0.79%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.63 (+0.79%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
S&P 500   3,294.79 (+0.42%)
DOW   27,147.51 (+0.00%)
QQQ   269.63 (+0.79%)
AAPL   110.09 (+0.01%)
MSFT   204.82 (+1.13%)
FB   252.22 (+1.64%)
GOOGL   1,444.30 (+0.99%)
AMZN   3,081.99 (+4.10%)
NVDA   496.22 (-0.89%)
TSLA   427.88 (-4.79%)
BABA   272.95 (-0.32%)
CGC   15.94 (+1.27%)
GE   6.24 (-1.73%)
MU   49.16 (+0.02%)
AMD   76.36 (-2.03%)
T   28.52 (-0.38%)
F   6.79 (-1.16%)
ACB   7.29 (+15.35%)
GILD   63.44 (-1.20%)
NFLX   484.97 (-0.49%)
DIS   126.16 (+0.60%)
BAC   23.83 (-2.62%)
BA   155.40 (-0.61%)
Log in
NASDAQ:PBYI

Puma Biotechnology News Headlines

$10.14
+0.24 (+2.42 %)
(As of 09/22/2020 01:18 PM ET)
Add
Compare
Today's Range
$9.80
Now: $10.14
$10.14
50-Day Range
$9.50
MA: $10.17
$11.14
52-Week Range
$5.50
Now: $10.14
$15.00
Volume4,398 shs
Average Volume1.32 million shs
Market Capitalization$402.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines Today

Source:
DateHeadline
Puma Biotechnology (NASDAQ:PBYI) Rating Increased to Sell at BidaskClubPuma Biotechnology (NASDAQ:PBYI) Rating Increased to Sell at BidaskClub
marketbeat.com - September 19 at 5:14 AM
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by BidaskClubPuma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by BidaskClub
marketbeat.com - August 29 at 9:43 AM
Zacks Investment Research Lowers Puma Biotechnology (NASDAQ:PBYI) to HoldZacks Investment Research Lowers Puma Biotechnology (NASDAQ:PBYI) to Hold
marketbeat.com - August 11 at 1:46 PM
Insider Selling: Puma Biotechnology Inc (NASDAQ:PBYI) Director Sells 9,703 Shares of StockInsider Selling: Puma Biotechnology Inc (NASDAQ:PBYI) Director Sells 9,703 Shares of Stock
americanbankingnews.com - September 17 at 6:53 PM
Puma Biotechnology (NASDAQ:PBYI) Trading Up 8%Puma Biotechnology (NASDAQ:PBYI) Trading Up 8%
americanbankingnews.com - September 14 at 7:43 PM
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment ConferencePuma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 8 at 7:14 PM
Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?
finance.yahoo.com - September 5 at 1:42 PM
-$0.33 Earnings Per Share Expected for Puma Biotechnology Inc (NASDAQ:PBYI) This Quarter-$0.33 Earnings Per Share Expected for Puma Biotechnology Inc (NASDAQ:PBYI) This Quarter
americanbankingnews.com - September 2 at 10:35 AM
Puma Biotech announces new data on strategies to improve tolerability of neratinibPuma Biotech announces new data on strategies to improve tolerability of neratinib
seekingalpha.com - August 19 at 6:55 PM
Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of OncologyPuma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology
finance.yahoo.com - August 19 at 6:54 PM
Puma Bio: A Contrarian Investment That Requires PatiencePuma Bio: A Contrarian Investment That Requires Patience
seekingalpha.com - August 17 at 2:14 PM
Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
finance.yahoo.com - August 11 at 4:36 PM
Puma Biotechnology Inc (PBYI) Q2 2020 Earnings Call TranscriptPuma Biotechnology Inc (PBYI) Q2 2020 Earnings Call Transcript
fool.com - August 7 at 4:16 PM
Pumas (PBYI) Earnings and Revenues Beat Estimates in Q2Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
nasdaq.com - August 7 at 3:11 PM
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
finance.yahoo.com - August 7 at 3:11 PM
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call TranscriptPuma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 7 at 10:10 AM
Recap: Puma Biotechnology Q2 EarningsRecap: Puma Biotechnology Q2 Earnings
finance.yahoo.com - August 6 at 11:53 PM
Puma Biotech (PBYI) Tops Q2 Earnings and Revenue EstimatesPuma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates
finance.yahoo.com - August 6 at 11:53 PM
Puma Biotechnology EPS beats by $0.20, beats on revenuePuma Biotechnology EPS beats by $0.20, beats on revenue
seekingalpha.com - August 6 at 6:53 PM
Puma Biotechnology Reports Second Quarter 2020 Financial ResultsPuma Biotechnology Reports Second Quarter 2020 Financial Results
finance.yahoo.com - August 6 at 6:53 PM
Puma Biotechnology Q2 Earnings PreviewPuma Biotechnology Q2 Earnings Preview
seekingalpha.com - August 5 at 10:48 PM
Did Hedge Funds Make The Right Call On Puma Biotechnology Inc (PBYI)Did Hedge Funds Make The Right Call On Puma Biotechnology Inc (PBYI)
finance.yahoo.com - July 28 at 3:03 PM
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical CancersPuma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
finance.yahoo.com - July 27 at 1:01 PM
Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus NetworkAcentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx® (neratinib) to Health Systems and Hospitals in the Acentrus Network
finance.yahoo.com - July 21 at 9:53 AM
Puma Biotech to provide Nerlynx access to Acentrus SpecialtyPuma Biotech to provide Nerlynx access to Acentrus Specialty
seekingalpha.com - July 21 at 9:53 AM
Puma Bios Nerlynx OKd in MalaysiaPuma Bio's Nerlynx OK'd in Malaysia
seekingalpha.com - July 16 at 5:48 PM
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage ...Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage ...
www.businesswire.com - July 16 at 5:48 PM
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast CancerPuma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
finance.yahoo.com - July 16 at 5:48 PM
Puma Biotechnology Clears Technical Benchmark, Hitting 80-Plus RS RatingPuma Biotechnology Clears Technical Benchmark, Hitting 80-Plus RS Rating
finance.yahoo.com - July 8 at 10:59 PM
Should You Buy Puma Biotechnology Inc (PBYI)?Should You Buy Puma Biotechnology Inc (PBYI)?
finance.yahoo.com - June 22 at 4:27 PM
Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?Puma Biotech (PBYI) Up 7.5% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - June 6 at 1:45 PM
Moving Average Crossover Alert: Puma BiotechnologyMoving Average Crossover Alert: Puma Biotechnology
finance.yahoo.com - May 26 at 12:32 PM
Puma Biotechnology: Still Bullish At These PricesPuma Biotechnology: Still Bullish At These Prices
seekingalpha.com - May 14 at 5:20 PM
Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?Puma Biotechnology, Inc. (PBYI) Shares March Higher, Can It Continue?
finance.yahoo.com - May 14 at 12:19 PM
Pumas (PBYI) Earnings and Revenues Beat Estimates in Q1Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1
www.nasdaq.com - May 11 at 4:47 PM
Analysts Have Made A Financial Statement On Puma Biotechnology, Inc.s (NASDAQ:PBYI) First-Quarter ReportAnalysts Have Made A Financial Statement On Puma Biotechnology, Inc.'s (NASDAQ:PBYI) First-Quarter Report
finance.yahoo.com - May 11 at 4:47 PM
Puma Biotechnology Inc (PBYI) Q1 2020 Earnings Call TranscriptPuma Biotechnology Inc (PBYI) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 9 at 4:38 PM
Edited Transcript of PBYI earnings conference call or presentation 7-May-20 8:30pm GMTEdited Transcript of PBYI earnings conference call or presentation 7-May-20 8:30pm GMT
finance.yahoo.com - May 8 at 10:31 PM
Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2020 Results - Earnings Call TranscriptPuma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:31 PM
Nerlynx sales up 7% in Q1Nerlynx sales up 7% in Q1
seekingalpha.com - May 7 at 7:08 PM
Puma Biotechnology Reports First Quarter 2020 Financial ResultsPuma Biotechnology Reports First Quarter 2020 Financial Results
finance.yahoo.com - May 7 at 7:08 PM
Puma Bios Nerlynx OKd in ChinaPuma Bio's Nerlynx OK'd in China
seekingalpha.com - May 7 at 2:07 PM
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early ...Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early ...
www.businesswire.com - May 7 at 2:07 PM
Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast CancerPuma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
finance.yahoo.com - May 7 at 9:05 AM
Puma Biotechnology Q1 2020 Earnings PreviewPuma Biotechnology Q1 2020 Earnings Preview
seekingalpha.com - May 7 at 4:05 AM
Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
finance.yahoo.com - May 7 at 4:05 AM
Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to DeclineEarnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline
finance.yahoo.com - April 30 at 5:06 PM
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South KoreaPuma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
finance.yahoo.com - April 30 at 5:06 PM
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial ResultsPuma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
www.businesswire.com - April 23 at 8:38 PM
Puma Biotechnology Earns 90 RS Rating, Edging Above 10-Week LinePuma Biotechnology Earns 90 RS Rating, Edging Above 10-Week Line
finance.yahoo.com - April 21 at 10:44 PM
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven?Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven?
finance.yahoo.com - April 8 at 12:40 PM
So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be PrematureSo Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature
www.fool.com - April 1 at 7:41 AM
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 25 at 5:43 PM
This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.